OBJECTIVE—To study determinants of incident hyperglycemia in rural Indian mothers 6 years after delivery.

RESEARCH DESIGN AND METHODS—The Pune Maternal Nutrition Study collected information in six villages near Pune on prepregnant characteristics and nutrition, physical activity, and glucose tolerance during pregnancy. An oral glucose tolerance test (OGTT) was repeated 6 years after delivery.

RESULTS—A total of 597 mothers had an OGTT at 28 weeks’ gestation; 3 had gestational diabetes (by World Health Organization 1999 criteria). Six years later, 42 of 509 originally normal glucose-tolerant mothers were hyperglycemic (8 diabetic, 20 with impaired glucose tolerance, and 14 with impaired fasting glucose). The hyperglycemic women had shorter legs and thicker skinfolds before pregnancy (P < 0.01, both), were less active and more hyperglycemic (2-h plasma glucose 4.8 vs. 4.4 mmol/l, P < 0.001) during pregnancy, and gained more weight during follow-up (6.0 vs. 2.7 kg, P < 0.001). Multivariate analysis revealed that total leukocyte count and blood pressure during pregnancy were additional independent predictors of 2-h glucose concentration at follow-up.

CONCLUSIONS—Our results suggest that compromised linear growth, adiposity, inflammation, and less physical activity predispose to hyperglycemia in young rural Indian women. International cut points of diabetes risk factors are largely irrelevant in these women.

India has the largest number of diabetic patients in any one country (1) and has been called the “diabetes capital” of the world. Risk factors for diabetes in Indians are mostly derived from cross-sectional surveys (2); there are only a few prospective studies of incident diabetes (3). Classic risk factors for type 2 diabetes include a family history of diabetes, higher age, greater obesity (total and central), and insulin resistance. Recent research has revealed a role for new genetic markers (4), adverse intrauterine environment and accelerated childhood growth (5), inflammation (6), and endothelial dysfunction (7). Interestingly, short height and short legs have also been associated with risk of type 2 diabetes (8).

There is growing recognition that pregnancy is a window revealing future metabolic and cardiovascular risk for the mother (9). Hormonal, metabolic, and inflammatory stresses of pregnancy unmask underlying susceptibility to diabetes. The original definition of gestational diabetes mellitus (GDM) was based on the level of glycemia that predicts future risk of diabetes (10). Over two-thirds of GDM women in our clinic were hyperglycemic within 4 years of delivery (11), one of the highest rates anywhere. There is little community-based information in India on the predictive value of measurements during pregnancy for future risk of diabetes.

The Pune Maternal Nutrition Study (PMNS) is a community-based study of maternal nutrition, metabolism, and fetal growth in six villages near Pune, Maharashtra, India (12). Women were enrolled before pregnancy, and during pregnancy, anthropometric, nutritional, and biochemical-metabolic measurements were made, including a 75-g oral glucose tolerance test (OGTT). The OGTT was performed 6 years after delivery, providing an opportunity to study risk factors in pregnancy for future hyperglycemia.

The study design and methods of the PMNS have been described (12). We identified 2,675 married nonpregnant women for possible enrolment, and 2,466 agreed to participate. Field workers recorded menstrual dates, detailed anthropometry, and socio-economic status (SES) using a standardized questionnaire. Women missing two successive periods underwent an ultrasound examination; singleton pregnancies of <21 weeks’ gestation were included.

Maternal measurements in pregnancy

At 18 ± 2 and 28 ± 2 weeks’ gestation, we measured anthropometry and dietary intakes using a semi-weighted 24-h recall method and a food frequency questionnaire. A structured questionnaire was used to record typical daily routine, which included farming and domestic activities. Using published data on the energy cost of various activities, a weighted total daily score was derived (13). At 28 weeks, an OGTT (75-g anhydrous glucose) was performed and venous blood samples obtained fasting and 2-h postglucose.

Blood measurements included hemoglobin, total leukocyte count (TLC), platelet count (Beckman Coulter T540), plasma glucose, total cholesterol, and triglyceride concentrations using standard kits and insulin, proinsulin, and 32–33 split proinsulin using a Delfia assay. Insulin resistance was calculated from the homeostasis model assessment equation (14). Glucose tolerance was classified by World Health Organization 1999 criteria (15). At delivery, we made detailed measurements of the baby’s size. Enrollment started in June 1994, and the last delivery occurred in November 1996.

Maternal measurements at 6-year follow-up

The women were invited for an OGTT 6 years after delivery (2000–2002). They arrived the evening before, were given a standard dinner, and rested overnight (only water by mouth). A 75-g OGTT was carried out next morning. Information on medical events and pregnancies since the index delivery was recorded by trained medical officer using a questionnaire. Anthropometric measurements included height and sitting height to the nearest 1 mm using a Harpenden stadiometer. Blood pressure was recorded in the supine position using an automated machine (UA 767PC; A and D Instruments, Abingdon, Oxford, U.K.). SES before pregnancy was assessed using the Kuppuswamy score (16) and at the 6-year follow-up using the National Family Health Survey-2 standard of living index (17).

Definitions and calculations

Impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), and diabetes were diagnosed per World Health Organization 1999 criteria (15). Metabolic syndrome was defined using International Diabetes Federation 2006 criteria (18). Fat mass was calculated from four skinfolds by Durnin’s method (19) and leg length by subtracting sitting height from total height. Preterm birth was defined as a delivery before 37 weeks’ gestation. Babies weighing <2,500 g at birth were defined as having low birth weight. Babies with weight above the gestation and sex-specific 90th percentile were defined as large for gestational age and those below the 10th percentile as small for gestational age. Adverse fetal outcome was defined as a history of any of the following: two or more spontaneous abortions, a stillbirth, neonatal death, or preterm delivery.

Ethical permission for the study was granted by the KEM Hospital Ethical Committee and by the local village leaders. The women signed written informed consent.

Statistical methods

Data are presented as means ± SD. Variables with skewed distributions (subscapular and triceps skinfold thickness and maternal insulin concentrations) were log transformed to satisfy assumptions of normality. Pearson correlation coefficients were used to study associations. Multiple linear and logistic regression and ANOVA models were used to assess whether associations were independent of potential confounding factors. Analyses were carried out using STATA (version 7.0).

Of 814 pregnancies enrolled in the PMNS, 770 mothers delivered normal, live, single babies. A total of 597 women had an OGTT. Three were diagnosed with GDM and excluded from the analysis of incident hyperglycemia. Of 594 normal glucose-tolerant mothers, 4 who delivered stillbirths and 28 whose children died were not followed up; 7 mothers died, 11 were pregnant, and 31 declined to participate. Thus, an OGTT was performed on 513 nonpregnant mothers: 4 vomited, and 509 completed the test (94% of eligible). Fourteen mothers were classified as IFG, 20 as IGT, and 8 as diabetic; together they are referred to as hyperglycemic and the rest as normoglycemic (n = 467) (Fig. 1). Women who did not have an OGTT during pregnancy (n = 173) and those who were not followed up did not differ in age, BMI, and SES compared with those who were studied.

Characteristics of the women at 6-year follow-up

Hyperglycemic women were of similar age, SES, and parity compared with normoglycemic women (Table 1). None of these women reported a first-degree relative with diabetes. Hyperglycemic women were shorter, heavier, and had higher BMI, higher waist and hip circumferences and waist-to-hip ratios, thicker skinfolds, and higher percentages of body fat. Their shorter height was mostly accounted for by shorter legs. Hyperglycemic women gained more weight over the period of the study and had higher blood pressure, fasting plasma triglyceride concentrations, and TLC. Fasting plasma insulin concentrations and homeostasis model assessment of insulin resistance were similar in the two groups. Fifteen percent of the hyperglycemic and 1% of the normoglycemic women had the metabolic syndrome.

Prepregnancy and pregnancy characteristics

Hyperglycemic women reported a larger number of adverse fetal outcomes (mostly abortions) but had similar parity (Table 2). They had larger skinfolds and marginally higher percentages of body fat and waist circumference.

At 28 weeks’ gestation, the subsequently hyperglycemic women had higher 2-h plasma glucose concentrations (by OGTT) and higher blood pressure; other biochemical and hematological measurements were similar in the two groups. Macronutrient intake; frequencies of intake of green leafy vegetables, fruit, and milk; and circulating concentrations of vitamin B12, folate, vitamin C, and homocysteine were similar in the two groups (data not shown).

As a group, these women had high levels of physical activity. Domestic work included cooking, washing clothes and utensils, and fetching water and firewood. Farming activities included taking care of animals, milking animals, and farm labor. The hyperglycemic women had a lower physical activity score than the normoglycemic women due to lower domestic activity.

None of the PMNS women smoked. Ten percent (n = 4) of hyperglycemic women and 28% of normoglycemic women either chewed tobacco or used it as tooth powder (Mishri).

Birth weight and other anthropometric measurements of the newborns were similar in the two groups of women, as were the rates of low birth weight, small for gestational age, large for gestational age, and preterm delivery.

Multivariate associations of 2-h plasma glucose concentration and incident hyperglycemia at 6 years

We analyzed the associations of glycemic status at follow-up by two methods: 1) using 2-h plasma glucose concentration as a continuous variable and 2) using incident hyperglycemia (IFG + IGT + diabetes) as a categorical variable (Table 3 and online appendix Table 3B [available at http://dx.doi.org/10.2337/dc07-0329]).

Multiple linear regression analysis showed that higher 2-h plasma glucose concentration was associated with shorter legs and higher prepregnant fat mass, 2-h plasma glucose concentration, TLC, systolic blood pressure during pregnancy, and weight gain over 6 years. Age, SES, parity, prepregnant waist circumference, physical activity, plasma insulin concentrations during pregnancy, and birth weight of the child were not significantly associated in this analysis. Replacing prepregnant fat mass by BMI revealed that BMI was not related.

To assess the relative significance of the association of independent variables with 2-h plasma glucose concentration, we performed stepwise regression analysis, which serially selects the independent variable most correlated with the dependent variable while controlling for those already selected, and the process is repeated until the newly added variable fails to make a significant contribution to variance. The results are shown in online appendix Table 3B. The contribution was 2.3% for weight gain, followed by prepregnant fat mass (2.6%), leukocyte count (1.4%), 2-h glucose (1.5%), and systolic blood pressure (0.9%) at 28 weeks’ gestation. Age, SES score, parity, prepregnant waist circumference, physical activity and fasting insulin at 28 weeks’ gestation, and birth weight of child and leg length of the mother were not contributory.

Logistic regression analysis showed that incident hyperglycemia was predicted by shorter leg length and lower physical activity during pregnancy. Age, SES, parity, prepregnant waist circumference, fat mass, 2-h glucose concentration and plasma insulin concentrations, TLC, blood pressure during pregnancy, and birth weight of the child were not significant predictors in this analysis. The results were very similar when the incident hyperglycemia was restricted to IGT + diabetes.

This is the first community-based study in India to report on incident hyperglycemia in rural women. Eight percent of these young women developed fasting or postglucose hyperglycemia between 21 and 28 years of age. Hyperglycemic women were shorter (especially in the legs) and more adipose from prepregnancy, and at the time of diagnosis had higher BMI, waist circumference, waist-to-hip ratio, and percentage of body fat than the normoglycemic women. However, by international standards, many of these women were underweight and thin: of the hyperglycemic women, 26 (62%) had a BMI <18.5 kg/m2 prepregnancy and 14 (33%) at the time of diagnosis of hyperglycemia. Our results support the previous finding that the thin-fat phenotype predisposes to type 2 diabetes (20). It is also clear that the international cut points for obesity and central obesity are inappropriate in young rural Indian women. The recently suggested cut point of BMI for obesity-related public health action in Asians (23 kg/m2) (21) also seems far too high for these rural Indian women.

In our study, shortness and fatness independently predicted higher glycemia, and the short and fat women were the most hyperglycemic. Short stature reflects a deficit in linear growth in early life, contributed both by genetic and nutritional factors; it is a risk factor for GDM, type 2 diabetes, hypertension, and coronary heart disease (8,22,23). Short legs represent a caudal diminution of growth and may represent intrauterine programming of body proportions. Increasing adiposity in a short individual reflects a rapid nutritional transition and increases the risk of type 2 diabetes, even in young rural Indian women.

A number of measurements during pregnancy were predictive of later hyperglycemia. These included higher postglucose glycemia, higher blood pressure, and higher TLC (all within the “normal” range). The plasma glucose concentrations during the pregnancies of subsequently hyperglycemic women were far below currently used cut points for diagnosis of GDM, suggesting that the gradient of risk may be very steep in susceptible populations. Higher glycemia was associated with higher TLC in pregnancy and at follow-up, suggesting an association with inflammation. TLC and other inflammatory markers are predictive of incident diabetes in Pima Indians, as shown in the Atherosclerosis Risk in Communities study (24,25). “Inflammation” could reflect heightened “innate” immunity (6). However, in pregnancy, it could be a maternal response to the conceptus (26), and the placenta secretes a number of proinflammatory cytokines (interleukin-6, tumor necrosis factor-α, leptin, etc.) (27). Association between higher blood pressure and hyperglycemia could reflect endothelial dysfunction, which also contributes to type 2 diabetes susceptibility (7). Thus, our results suggest that metabolic, inflammatory, and vascular changes in pregnancy predict future hyperglycemia and support the concept that pregnancy is a window on future health and disease.

Incident hyperglycemia (IFG + IGT + diabetes) was predicted by short legs, lower physical activity during pregnancy, and higher weight gain. In this farming community, physical activity during pregnancy is a surrogate of habitual physical activity, which is quite high. The typical daily activity of the hyperglycemic women far exceeds the current recommendations for physical activity to prevent diabetes (150 min walking per week) (28). Finally, weight gain predicted incident hyperglycemia. This is too well known and operates through increased insulin resistance.

Our study has many strengths. We made a wide range of measurements specifically designed to answer relevant hypotheses. The community participation and follow-up rates are high (>90%). The rural Indians represent 70% of India’s population, who will contribute increasingly to the burgeoning epidemic of diabetes in India. Our findings therefore provide useful public health information for the policy makers. One weakness is that leg length was measured only at follow-up; however, it is fairly stable in young adults.

Our findings suggest possible interventions to reduce the incidence of diabetes in Indians. There is a need to take a “life-course” approach and include measures to promote skeletal and lean growth in early life, to promote physical activity, and to eliminate sources of chronic inflammation. In practical terms, active prevention of weight gain in people who are “thin” by the currently accepted norms will be a challenging task.

Figure 1—

Study subjects. DM, diabetes; GTT, glucose tolerance test; NGT, normal glucose tolerance; WHO, World Health Organization.

Figure 1—

Study subjects. DM, diabetes; GTT, glucose tolerance test; NGT, normal glucose tolerance; WHO, World Health Organization.

Close modal
Table 1—

Anthropometric and biochemical characteristics of the mothers at follow-up (6 years after the index pregnancy) according to current glycemic status (by World Health Organization 1999 criteria)

NormoglycemicHyperglycemicPP*
n 467 42   
Age (years) 27.9 ± 3.5 28.6 ± 4.5 0.258 — 
Completed secondary school 330 (53.6) 39 (68.4) 0.128 — 
Upper SES (upper quartile of score) 180 (31.4) 18 (36.7) 0.694 — 
Deliveries after index delivery 1.6 ± 0.9 1.7 ± 0.9 0.671 0.525 
Weight (kg) 44.4 ± 6.9 47.7 ± 8.9 0.004 0.026 
Height (cm) 152.1 ± 5.0 150.4 ± 4.4 0.040 0.063 
Leg length (cm) 73.5 ± 3.9 71.4 ± 4.5 0.001 0.001 
BMI (kg/m218.9 ± 2.6 20.9 ± 3.8 0.0001 0.0001 
Waist (cm) 65.6 ± 6.9 70.3 ± 11.1 0.0001 0.002 
Hip (cm) 85.4 ± 6.8 88.6 ± 10.1 0.012 0.028 
Waist-to-hip ratio 0.77 ± 0.06 0.79 ± 0.09 0.010 0.043 
Sum of four skinfolds (mm) 37.1 ± 17.6 49.4 ± 25.1 0.0001 0.0001 
Body fat % (from four skinfolds) 22.0 ± 5.8 25.2 ± 7.3 0.001 0.003 
Weight gain prepregnancy to 6-year follow-up (kg) 2.7 ± 5.1 6.0 ± 6.8 0.0001 0.0001 
Fat mass gain prepregnancy to 6-year follow-up (kg) 1.2 ± 3.5 2.9 ± 4.5 0.004 0.007 
Fasting plasma glucose (mmol/l) 5.1 ± 0.5 6.2 ± 1.8 0.0001 0.0001 
2-h plasma glucose (OGTT) (mmol/l) 5.2 ± 1.1 8.8 ± 3.4 0.0001 0.0001 
Fasting plasma insulin (pmol/l) 35.4 ± 34.0 37.5 ± 24.3 0.701 0.620 
Insulin resistance (HOMA-IR) 0.65 ± 0.56 0.77 ± 0.52 0.129 0.150 
Blood pressure (mmHg) 107/64 ± 9/7 115/68 ± 10/7 0.0001 0.0001 
Plasma total cholesterol (mmol/l) 3.6 ± 0.7 3.8 ± 0.7 0.168 0.402 
Plasma HDL cholesterol (mmol/l) 1.2 ± 0.3 1.2 ± 0.3 0.363 0.385 
Plasma triglycerides (mmol/l) 0.7 ± 0.3 1.0 ± 1.4 0.0001 0.0001 
TLC (×109/l) 7.2 ± 1.6 7.8 ± 2.1 0.045 0.053 
Metabolic syndrome (IDF 2005 criteria) 7 (1.2) 8 (15.4) 0.0001 — 
NormoglycemicHyperglycemicPP*
n 467 42   
Age (years) 27.9 ± 3.5 28.6 ± 4.5 0.258 — 
Completed secondary school 330 (53.6) 39 (68.4) 0.128 — 
Upper SES (upper quartile of score) 180 (31.4) 18 (36.7) 0.694 — 
Deliveries after index delivery 1.6 ± 0.9 1.7 ± 0.9 0.671 0.525 
Weight (kg) 44.4 ± 6.9 47.7 ± 8.9 0.004 0.026 
Height (cm) 152.1 ± 5.0 150.4 ± 4.4 0.040 0.063 
Leg length (cm) 73.5 ± 3.9 71.4 ± 4.5 0.001 0.001 
BMI (kg/m218.9 ± 2.6 20.9 ± 3.8 0.0001 0.0001 
Waist (cm) 65.6 ± 6.9 70.3 ± 11.1 0.0001 0.002 
Hip (cm) 85.4 ± 6.8 88.6 ± 10.1 0.012 0.028 
Waist-to-hip ratio 0.77 ± 0.06 0.79 ± 0.09 0.010 0.043 
Sum of four skinfolds (mm) 37.1 ± 17.6 49.4 ± 25.1 0.0001 0.0001 
Body fat % (from four skinfolds) 22.0 ± 5.8 25.2 ± 7.3 0.001 0.003 
Weight gain prepregnancy to 6-year follow-up (kg) 2.7 ± 5.1 6.0 ± 6.8 0.0001 0.0001 
Fat mass gain prepregnancy to 6-year follow-up (kg) 1.2 ± 3.5 2.9 ± 4.5 0.004 0.007 
Fasting plasma glucose (mmol/l) 5.1 ± 0.5 6.2 ± 1.8 0.0001 0.0001 
2-h plasma glucose (OGTT) (mmol/l) 5.2 ± 1.1 8.8 ± 3.4 0.0001 0.0001 
Fasting plasma insulin (pmol/l) 35.4 ± 34.0 37.5 ± 24.3 0.701 0.620 
Insulin resistance (HOMA-IR) 0.65 ± 0.56 0.77 ± 0.52 0.129 0.150 
Blood pressure (mmHg) 107/64 ± 9/7 115/68 ± 10/7 0.0001 0.0001 
Plasma total cholesterol (mmol/l) 3.6 ± 0.7 3.8 ± 0.7 0.168 0.402 
Plasma HDL cholesterol (mmol/l) 1.2 ± 0.3 1.2 ± 0.3 0.363 0.385 
Plasma triglycerides (mmol/l) 0.7 ± 0.3 1.0 ± 1.4 0.0001 0.0001 
TLC (×109/l) 7.2 ± 1.6 7.8 ± 2.1 0.045 0.053 
Metabolic syndrome (IDF 2005 criteria) 7 (1.2) 8 (15.4) 0.0001 — 

Data are n (%) and means ± SD.

*

Statistical significance after adjusting for maternal age and SES at the time of the measurements, by ANOVA. HOMA-IR, homeostasis model assessment of insulin resistance; IDF, International Diabetes Federation.

Table 2—

Maternal characteristics before and during the index pregnancy according to glycemic status at 6-year follow-up

NormoglycaemicHyperglycemicPP*
n 467 42   
Prepregnancy     
    Adverse fetal outcome (%) 24 (5.2) 8 (19.0) 0.0001 — 
    Parity 1.2 ± 1.2 1.3 ± 1.3 0.630 0.837 
    Tobacco use (%) 132 (28.3) 4 (9.5) — — 
    Weight (kg) 41.7 ± 4.9 41.6 ± 6.9 0.950 0.991 
    BMI (kg/m218.0 ± 1.8 18.4 ± 2.8 0.232 0.261 
    Waist (cm) 60.5 ± 5.4 62.2 ± 8.5 0.069 0.075 
    Hip (cm) 81.4 ± 4.9 82.0 ± 6.5 0.465 0.514 
    Waist-to-hip ratio 0.74 ± 0.06 0.76 ± 0.08 0.180 0.179 
    Sum of four skinfolds (mm) 33.8 ± 12.3 38.7 ± 18.1 0.018 0.028 
    Body fat % (from four skinfolds) 20.9 ± 4.2 22.4 ± 5.4 0.044 0.071 
28 weeks’ gestation     
    Hemoglobin (g/l) 112.0 ± 15.0 114.0 ± 12.0 0.363 0.279 
    Fasting plasma glucose (mmol/l) 3.9 ± 0.6 4.1 ± 0.8 0.180 0.178 
    2-h plasma glucose (OGTT) (mmol/l) 4.4 ± 1.0 4.8 ± 1.4 0.008 0.009 
    Fasting plasma insulin (pmol/l) 23.5 ± 37.9 20.6 ± 14.1 0.635 0.531 
    Pro-insulin (pmol/l) 2.5 ± 2.1 2.5 ± 1.9 0.983 0.992 
    32–33 split pro-insulin (pmol/l) 3.4 ± 4.4 3.2 ± 2.7 0.812 0.885 
    Pro-insulin–to–insulin ratio 0.21 ± 0.33 0.15 ± 0.12 0.273 0.288 
    Insulin resistance (HOMA-IR) 0.78 ± 1.1 0.73 ± 0.57 0.770 0.641 
    Blood pressure (mmHg) 112/62 ± 9/8 115/64 ± 9/3 0.055 0.078 
    Plasma total cholesterol (mmol/l) 4.8 ± 0.9 4.9 ± 0.8 0.713 0.652 
    Plasma HDL cholesterol (mmol/l) 1.1 ± 0.3 1.1 ± 0.3 0.224 0.190 
    Plasma triglycerides (mmol/l) 1.5 ± 0.5 1.6 ± 0.7 0.282 0.323 
    TLC (×109/l) 9.1 ± 1.9 9.5 ± 2.5 0.286 0.282 
    Macro nutrient intake/day     
Total energy (kcal) 1,690.8 ± 498.3 1,623.4 ± 441.8 0.408 0.753 
Protein (g) 44.1 ± 13.9 42.9 ± 12.5 0.598 0.991 
Fat (g) 32.6 ± 13.8 31.9 ± 11.9 0.747 0.914 
Carbohydrate (g) 304.9 ± 89.8 290.0 ± 80.5 0.311 0.591 
    Activity scores     
Total 65.7 ± 25.3 51.8 ± 24.6 0.001 0.003 
Domestic 28.7 ± 13.2 23.3 ± 17.6 0.019 0.031 
Farming 27.2 ± 15.7 23.3 ± 16.5 0.295 0.348 
At delivery     
    Preterm delivery (%) 60 (9.7) 5 (8.6) 0.507 — 
    Caesarean section (%) 21 (4.5) 2 (4.8) 0.986 — 
    Birth weight (g)† 2,646 ± 363 2,628 ± 425 0.775 0.709 
    Birth weight <2,500 g (%) 172 (38.0) 13 (33.0) 0.519 — 
    Birth weight >90th centile (LGA) (%) 35 (7.9) 4 (10.3) 0.599 — 
    Birth weight <10th centile (SGA) (%) 44 (9.9) 5 (12.8) 0.560 — 
NormoglycaemicHyperglycemicPP*
n 467 42   
Prepregnancy     
    Adverse fetal outcome (%) 24 (5.2) 8 (19.0) 0.0001 — 
    Parity 1.2 ± 1.2 1.3 ± 1.3 0.630 0.837 
    Tobacco use (%) 132 (28.3) 4 (9.5) — — 
    Weight (kg) 41.7 ± 4.9 41.6 ± 6.9 0.950 0.991 
    BMI (kg/m218.0 ± 1.8 18.4 ± 2.8 0.232 0.261 
    Waist (cm) 60.5 ± 5.4 62.2 ± 8.5 0.069 0.075 
    Hip (cm) 81.4 ± 4.9 82.0 ± 6.5 0.465 0.514 
    Waist-to-hip ratio 0.74 ± 0.06 0.76 ± 0.08 0.180 0.179 
    Sum of four skinfolds (mm) 33.8 ± 12.3 38.7 ± 18.1 0.018 0.028 
    Body fat % (from four skinfolds) 20.9 ± 4.2 22.4 ± 5.4 0.044 0.071 
28 weeks’ gestation     
    Hemoglobin (g/l) 112.0 ± 15.0 114.0 ± 12.0 0.363 0.279 
    Fasting plasma glucose (mmol/l) 3.9 ± 0.6 4.1 ± 0.8 0.180 0.178 
    2-h plasma glucose (OGTT) (mmol/l) 4.4 ± 1.0 4.8 ± 1.4 0.008 0.009 
    Fasting plasma insulin (pmol/l) 23.5 ± 37.9 20.6 ± 14.1 0.635 0.531 
    Pro-insulin (pmol/l) 2.5 ± 2.1 2.5 ± 1.9 0.983 0.992 
    32–33 split pro-insulin (pmol/l) 3.4 ± 4.4 3.2 ± 2.7 0.812 0.885 
    Pro-insulin–to–insulin ratio 0.21 ± 0.33 0.15 ± 0.12 0.273 0.288 
    Insulin resistance (HOMA-IR) 0.78 ± 1.1 0.73 ± 0.57 0.770 0.641 
    Blood pressure (mmHg) 112/62 ± 9/8 115/64 ± 9/3 0.055 0.078 
    Plasma total cholesterol (mmol/l) 4.8 ± 0.9 4.9 ± 0.8 0.713 0.652 
    Plasma HDL cholesterol (mmol/l) 1.1 ± 0.3 1.1 ± 0.3 0.224 0.190 
    Plasma triglycerides (mmol/l) 1.5 ± 0.5 1.6 ± 0.7 0.282 0.323 
    TLC (×109/l) 9.1 ± 1.9 9.5 ± 2.5 0.286 0.282 
    Macro nutrient intake/day     
Total energy (kcal) 1,690.8 ± 498.3 1,623.4 ± 441.8 0.408 0.753 
Protein (g) 44.1 ± 13.9 42.9 ± 12.5 0.598 0.991 
Fat (g) 32.6 ± 13.8 31.9 ± 11.9 0.747 0.914 
Carbohydrate (g) 304.9 ± 89.8 290.0 ± 80.5 0.311 0.591 
    Activity scores     
Total 65.7 ± 25.3 51.8 ± 24.6 0.001 0.003 
Domestic 28.7 ± 13.2 23.3 ± 17.6 0.019 0.031 
Farming 27.2 ± 15.7 23.3 ± 16.5 0.295 0.348 
At delivery     
    Preterm delivery (%) 60 (9.7) 5 (8.6) 0.507 — 
    Caesarean section (%) 21 (4.5) 2 (4.8) 0.986 — 
    Birth weight (g)† 2,646 ± 363 2,628 ± 425 0.775 0.709 
    Birth weight <2,500 g (%) 172 (38.0) 13 (33.0) 0.519 — 
    Birth weight >90th centile (LGA) (%) 35 (7.9) 4 (10.3) 0.599 — 
    Birth weight <10th centile (SGA) (%) 44 (9.9) 5 (12.8) 0.560 — 

Data are n (%) and means ± SD.

*

Statistical significance after adjusting for maternal age and socioeconomic status at the time of the measurements, by ANOVA. †Birth weight adjusted for gestation and sex. HOMA-IR, homeostasis model assessment of insulin resistance; LGA, large for gestational age; SGA, small for gestational age.

Table 3—

Multiple linear regression analysis of predictors of 2-h plasma glucose concentrations during the OGTT 6 years after delivery and multiple logistic regression analysis of predictors of incident hyperglycemia (IFG + IGT + diabetres, World Health Organization 1999 criteria) 6 years after delivery

Predictors of 2-h glucose
Predictors of incident hyperglycemia
β95% CIPOR95% CI of ORP
Age (years) 0.037 0.0272–0.0468 0.554 0.911 0.776–1.071 0.259 
SES 0.046 0.0421–0.0499 0.360 0.967 0.909–1.029 0.295 
Parity −0.010 −0.0394 to 0.0194 0.877 1.321 0.822–2.125 0.250 
Prepregnant       
    Leg length (cm) −0.120 −0.1259 to −0.1141 0.019 0.875 0.802–0.954 0.003 
    Waist circumference (cm) 0.038 −0.0321 to 0.0439 0.534 1.014 0.926–1.110 0.764 
    Fat mass (kg) 0.161 0.1473–0.1747 0.014 1.140 0.955–1.361 0.148 
At 28 weeks’ gestation       
    Physical activity −0.030 −0.0319 to −0.0280 0.561 0.974 0.954–0.995 0.014 
    2-h glucose (mmol/l) 0.112 0.1100–0.1139 0.023 1.011 0.991–1.031 0.296 
    Fasting insulin (pmol/l) 0.036 0.0340–0.0379 0.454 0.991 0.966–1.016 0.469 
    TLC (×109/l) 0.112 0.0983–0.1257 0.021 1.083 0.907–1.294 0.378 
    Systolic blood pressure (mmHg) 0.098 0.0960–0.0999 0.047 1.025 0.982–1.069 0.261 
At delivery       
    Birth weight of child (g) (gestation and sex adjusted) −0.066 −0.0954 to −0.0366 0.188 0.738 0.482–1.131 0.163 
    Weight gain prepregnancy to follow-up (kg) 0.160 0.1541–0.1659 0.001 1.064 0.998–1.134 0.057 
Predictors of 2-h glucose
Predictors of incident hyperglycemia
β95% CIPOR95% CI of ORP
Age (years) 0.037 0.0272–0.0468 0.554 0.911 0.776–1.071 0.259 
SES 0.046 0.0421–0.0499 0.360 0.967 0.909–1.029 0.295 
Parity −0.010 −0.0394 to 0.0194 0.877 1.321 0.822–2.125 0.250 
Prepregnant       
    Leg length (cm) −0.120 −0.1259 to −0.1141 0.019 0.875 0.802–0.954 0.003 
    Waist circumference (cm) 0.038 −0.0321 to 0.0439 0.534 1.014 0.926–1.110 0.764 
    Fat mass (kg) 0.161 0.1473–0.1747 0.014 1.140 0.955–1.361 0.148 
At 28 weeks’ gestation       
    Physical activity −0.030 −0.0319 to −0.0280 0.561 0.974 0.954–0.995 0.014 
    2-h glucose (mmol/l) 0.112 0.1100–0.1139 0.023 1.011 0.991–1.031 0.296 
    Fasting insulin (pmol/l) 0.036 0.0340–0.0379 0.454 0.991 0.966–1.016 0.469 
    TLC (×109/l) 0.112 0.0983–0.1257 0.021 1.083 0.907–1.294 0.378 
    Systolic blood pressure (mmHg) 0.098 0.0960–0.0999 0.047 1.025 0.982–1.069 0.261 
At delivery       
    Birth weight of child (g) (gestation and sex adjusted) −0.066 −0.0954 to −0.0366 0.188 0.738 0.482–1.131 0.163 
    Weight gain prepregnancy to follow-up (kg) 0.160 0.1541–0.1659 0.001 1.064 0.998–1.134 0.057 

We are grateful to the community and to the pregnant women who participated in our study. We thank the late Prof. C.N. Hales and his colleagues in Cambridge, U.K. for insulin assays; David Collis and the staff of the Special Hematology Laboratory, Southampton General Hospital, Southampton, U.K., for ferritin and folate assays; and Drs. Chris Bates, Glynn Harvey, and Jonathan Perkins at the MRC Resource Center for Human Nutrition Research, Cambridge, U.K., for vitamin C assays. We also thank Dr. A.D. Agate, Director, Agharkar Research Institute and the late Dr. V.N. Rao, Director, KEM Hospital Research Centre for providing the facilities. We acknowledge contributions by Drs. Siddhivnayak Hirve, Shobha Rao, Asawari Kanade, Arun Kinare, Monesh Shah, Asit Natekar, Manoj Chinchwadkar, Binu John, Anuja Bisht, and Mahananda Bhavikatti, as well as Sonali Rege, Poonam Gupta, Charu Joglekar, Parveen Bharucha, Vanessa Cox, and Pallavi Yajnik.

1.
International Diabetes Federation:
Diabetes Atlas: The eAtlas
[Web site]. Available at http://www.eatlas.idf.org/. Accessed 5 June 2007
2.
Ramachandran A: Epidemiology of diabetes in India: three decades of research.
J Assoc Physicians India
53
:
34
–38,
2005
3.
Yajnik CS, Shelgikar KM, Naik SS, et al.: Impairment of glucose tolerance over 10 yr in normal glucose tolerant Indians.
Diabetes Care
26
:
2212
–2213,
2003
4.
O’Rahilly S, Wareham NJ: Genetic variants and common diseases: better late than never.
N Engl J Med
355
:
306
–308,
2006
5.
Barker DJ: The developmental origins of insulin resistance.
Horm Res
64
:
2
–7,
2005
6.
Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.
Diabetes Care
27
:
813
–823,
2004
7.
Caballero AE: Endothelial dysfunction, inflammation, and insulin resistance:a focus on subjects at risk for type 2 diabetes.
Curr Diab Rep
4
:
237
–246,
2004
8.
Lawlor DA, Ebrahim S, Smith GD: The association between components of adult height and type 2 diabetes and insulin resistance: British Women’s Heart Study.
Diabetologia
45
:
1097
–1106,
2002
9.
Sattar N, Greer IA: Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?
BMJ
325
:
157
–160,
2002
10.
O’sullivan JB, Mahan CM: Criteria for the oral glucose tolerance test in pregnancy.
Diabetes
13
:
278
–285,
1964
11.
Kale SD, Yajnik CS, Kulkarni SR, et al.: High risk of diabetes and metabolic syndrome in Indian women with gestational diabetes mellitus.
Diabet Med
21
:
1257
–1258,
2004
12.
Rao SR, Yajnik CS, Kanade AS, et al.: Intake of micronutrient-rich foods in rural Indian mothers is associated with the size of their babies at birth: Pune Maternal Nutrition Study.
J Nutr
131
:
1217
–1224,
2001
13.
Kanade A, Rao S, Yajnik CS, et al.: Rapid assessment of maternal activity among rural Indian mothers (Pune Maternal Nutrition Study).
Public Health Nutr
8
:
588
–595,
2005
14.
Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling.
Diabetes Care
27
:
1487
–1495,
2004
16.
Pareek U, Trivedi G: Reliability and validity of socioeconomic scales.
Ind J Appl Psychol
1
:
34
–40,
1964
17.
International Institute for Population Sciences and ORC Macro 2001 National Family Health Survey (NFHS-2), India, 1998–99. Maharashtra, Mumbai, India, International Institute for Population Sciences, p. 52–57
18.
International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome [article online], 2006. Available from http://www.idf.org/webdata/docs/MetS_def_update2006.pdf. Accessed 18 August 2006
19.
Durnin JVGA, Womersley J: Body fat assessed from total density and its estimation from skinfold thickness: measurements of 481 men and women from 16 to 72 years.
Br J Nutr
32
:
77
–97,
1974
20.
Yajnik CS: Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries.
J Nutr
134
:
205
–210,
2004
21.
Appropriate body mass index for Asian populations and its implications for policy and intervention strategies, WHO Expert Consultation.
Lancet
363
:
157
–163,
2004
22.
Jang HC, Min HK, Lee HK, et al.: Short stature in Korean women: a contribution to the multifactorial predisposition to gestational diabetes mellitus.
Diabetologia
41
:
778
–783,
1998
23.
Asao K, Linda Kao WH, Baptiste-Roberts K, et al.: Short stature and the risk of adiposity, insulin resistance, and type 2 diabetes in middle age (NHANES III).
Diabetes Care
29
:
1632
–1637,
2006
24.
Krakoff J, Funahashi T, Stehouwer Coen DA, et al.: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indians.
Diabetes Care
26
:
1745
–1751,
2003
25.
Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study.
Lancet
353
:
1649
–1652,
1999
26.
Redman CW, Sargent IL: Latest advances in understanding preeclampsia.
Science
308
:
1592
–1594,
2005
27.
Radaelli T, Uvena-Celebrezze J, Minium J, et al.: Maternal interleukin-6: marker of fetal growth and adiposity.
J Soc Gynecol Investig
13
:
53
–57,
2006
28.
American Diabetes Association: Standards of medical care in diabetes—
2006
.
Diabetes Care
26(Suppl. 1)
:
S4
–S42,
2006

Published ahead of print at http://care.diabetesjournals.org on 9 July 2007. DOI: 10.2337/dc07-0329.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc07-0329.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.